[1]王万娥,李晶,李荣,等.解毒凉血法联合恩替卡韦抗病毒治疗慢性乙型肝炎临床疗效 及对患者炎症因子的影响研究[J].陕西中医,2018,(10):1387-1389.
　Wang Wane,Li Jing,Li Rong,et al.Effect of detoxification and cooling blood combined with entecavir antiviral therapy on chronic hepatitis B and its effect on inflammatory cytokines[J].,2018,(10):1387-1389.
点击复制

解毒凉血法联合恩替卡韦抗病毒治疗慢性乙型肝炎临床疗效 及对患者炎症因子的影响研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2018年10期
页码:
1387-1389
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Effect of detoxification and cooling blood combined with entecavir antiviral therapy on chronic hepatitis B and its effect on inflammatory cytokines
文章编号:
DOI: 10.3969/j.issn.1000-7369.2018.10.022
作者:
王万娥1; 李晶1; 李荣1; 王治新2△
1.江苏省淮安市第四人民医院(淮安 223002)，2.陕西省神木县医院（神木 719300）
Author(s):
Wang Wan’e; Li Jing; Li Rong; et al.
Fourth People’s Hospital of Huai’an in Jiangsu Province（Huainan 223002）
关键词:
乙型肝炎/中西医结合疗法清热解毒剂/治疗应用抗病毒药
Keywords:
Key words Hepatitis B/integrated Chinese traditional and western medicine therapyAntipyretic-Detoxicate agents / therapeutic useAntiviral agents
分类号:
R512.62
文献标志码:
A
摘要:
摘要 目的：探讨解毒凉血法联合恩替卡韦抗病毒治疗慢性乙型肝炎患者的临床疗效，并观察其对炎症因子的影响。方法:选取慢性乙型肝炎患者82例，按照治疗方式分组，采取单用恩替卡韦抗病毒疗法42例（对照组），基于对照组加用解毒凉血法40例（观察组），比较两组临床疗效及炎症因子水平。结果:两组治疗前肝功能指标、炎症因子及HBeAg、HBV-DNA水平比较无显著性差异（P＞0.05），治疗6个月后两组ALT、AST均明显低于本组治疗前，且观察组ALT、AST明显低于对照组；治疗后两组HBeAg、HBV-DNA水平均明显低于本组治疗前，且观察组HBeAg低于对照组；治疗后观察组TNF-α、IFN-γ、IL-6及IL-8均明显低于对照组与本组治疗前，比较有显著性差异（P＜0.05）。结论:解毒凉血法联合抗病毒治疗慢性乙型肝炎临床疗效较好，可有效降低炎症因子水平，值得应用。
Abstract:
Abstract Objective: To investigate the clinical efficacy of detoxification and cooling blood combined with antiviral therapy of entecavir in patients with chronic hepatitis B，and to observe their effects on inflammatory cytokines. Methods: 82 patients with chronic hepatitis B who were enrolled in this study. Twenty-four patients (control group) received entecavir anti-viral therapy alone and were treated with detoxification 40 cases of cooling blood method (observation group)，the clinical efficacy and the level of inflammatory cytokines in both groups were compared. Results:Before treatment，there was no significant difference in liver function indexes，inflammatory factors，HBeAg and HBV-DNA levels between the two groups (P＞0.05). After 6 months of treatment，ALT and AST in both groups were significantly lower than before treatment The levels of HBeAg and HBV-DNA in the two groups were significantly lower than those in the control group before treatment，and the HBeAg in the observation group was lower than that in the control group. After treatment，the levels of TNF-α，IFN-γ，IL-6 and IL-8 were significantly lower than the control group and the group before treatment，there was a significant difference (P＜0.05). Conclusion:detoxification and cooling blood combined with antiviral treatment of chronic hepatitis B has a good clinical efficacy，which can effectively reduce the level of inflammatory cytokines and is worth promoting.

参考文献/References:


[1] 田长印,张欣,刘拉羊,等.慢性乙型肝炎患者生命质量影响因素分析[J].中国感染控制杂志,2017,16(2):156-159.
[2]王潇,刘艳,严谨,等.慢性乙型肝炎患者的心理韧性[J].中国心理卫生杂志,2016,30(3):172-173.
[3]防治乙肝病毒的药物研究进展[J].国外医学:病毒学分册,2005,12(5):140-143.
[4]李宏峰,刘伟.血清 AFP 升高对乙肝患者的临床意义探讨[J].中国实验诊断学,2014,18(5):814-815.
[5]马汉骞.加用双环醇片治疗对核苷酸类似物变异及应答不佳而调整抗病毒治疗的慢性乙型肝炎的临床观察[J].首都医药,2013,20(4):32-34.
[6]李丰荣.重型病毒性肝炎临床治疗效果观察[J].中国实用医药,2016,11(17):204-205.
[7]倪霜玲,刘炉香,王树民，等.聚乙二醇干扰素联合核苷药对慢性乙肝伴肝硬化患者免疫功能的影响[J].中国生化药物杂志,2016,36(10):127-130.
[8]赖静兰,刘玉明,林春,等.血清白细胞介素-1受体拮抗剂与乙肝肝衰竭预后的相关性[J].中华全科医学,2016,14(5):718-720,745.
[9]袁红,蒋秀珠.某地区HIV、HCV、TP感染与HBV感染情况调查[J].国际检验医学杂志,2012,33(12):1444-1445,1447.
[10]王台.恩替卡韦治疗失代偿期乙型肝炎肝硬化36例两年疗效观察[J].陕西医学杂志,2012,41(1):87-89.
[11]张向磊,卢立伟,刘阳,等.基于中医传承辅助平台的中医药治疗乙肝肝硬化用药规律分析[J].世界中医药,2016,11(10):2160-2163.
[12]陈鹏,曹武奎.热毒清对急性肝损伤大鼠内毒素血症的影响[J].天津中医药,2013,30(4):228-231.
[13]高雪岩,孙建宁,王文全,等.赤芍总苷的制备及其对小鼠肝损伤的保护作用[J].中国实验方剂学杂志,2010,16(18):183-186.
[14]张湘东,许定舟,李金华,等.丹参多糖的免疫调节活性研究[J].中药材,2012,35(6):949-952.
[15]王军英,薛连彬.中西医结合治疗慢性乙型肝炎疗效观察[J].陕西中医,2015,36(7):845-846.

更新日期/Last Update: 2019-01-07